Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.

Vermeulen MA, van Deurzen CH, Schroder CP, Martens JW, van Diest PJ.

J Clin Pathol. 2019 Oct 25. pii: jclinpath-2019-206116. doi: 10.1136/jclinpath-2019-206116. [Epub ahead of print]

PMID:
31653758
2.

Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes.

Hammerl D, Massink MPG, Smid M, van Deurzen CHM, Meijers-Heijboer HEJ, Waisfisz Q, Debets R, Martens JWM.

Clin Cancer Res. 2019 Oct 24. doi: 10.1158/1078-0432.CCR-19-0285. [Epub ahead of print]

PMID:
31649042
3.

Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.

Dano H, Altinay S, Arnould L, Bletard N, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Jaffer S, Kurpershoek E, Lacroix-Triki M, Laka A, Lambein K, MacGrogan GM, Marchió C, Martinez DM, Nofech-Mozes S, Peeters D, Ravarino A, Reisenbichler E, Resetkova E, Sanati S, Schelfhout AM, Schelfhout V, Shaaban AM, Sinke R, Stanciu-Pop CM, Stobbe C, van Deurzen CHM, Van de Vijver K, Van Rompuy AS, Verschuere S, Vincent-Salomon A, Wen H, Bouzin C, Galant C, Van Bockstal MR.

Mod Pathol. 2019 Sep 18. doi: 10.1038/s41379-019-0367-9. [Epub ahead of print]

PMID:
31534203
4.

Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Agahozo MC, van Bockstal MR, Groenendijk FH, van den Bosch TPP, Westenend PJ, van Deurzen CHM.

Mod Pathol. 2019 Aug 2. doi: 10.1038/s41379-019-0331-8. [Epub ahead of print]

PMID:
31375764
5.

APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer.

Sieuwerts AM, Doebar SC, de Weerd V, Verhoef EI, Beauford CM, Agahozo MC, Martens JWM, van Deurzen CHM.

Cancers (Basel). 2019 Jul 27;11(8). pii: E1062. doi: 10.3390/cancers11081062.

6.

Correction: Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.

Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.

Clin Cancer Res. 2019 May 1;25(9):2935. doi: 10.1158/1078-0432.CCR-19-0936. No abstract available.

PMID:
31043383
7.

A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.

Van Bockstal MR, Agahozo MC, Koppert LB, van Deurzen CHM.

Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32362. [Epub ahead of print] Review.

PMID:
31018242
8.

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.

Berghuis AMS, van Deurzen CHM, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ.

Breast Cancer Res Treat. 2019 Jun;175(2):451-458. doi: 10.1007/s10549-019-05141-y. Epub 2019 Feb 13.

9.

The role of routine histopathology after chest-contouring surgery in transmen.

Van Bockstal MR, Monstrey SJ, van Deurzen CHM.

Eur J Surg Oncol. 2019 Mar;45(3):485-486. doi: 10.1016/j.ejso.2018.10.058. Epub 2018 Oct 18. No abstract available.

PMID:
30528044
10.

Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.

Doebar SC, Krol NM, van Marion R, Brouwer RWW, van Ijcken WFJ, Martens JM, Dinjens WNM, van Deurzen CHM.

Virchows Arch. 2019 Feb;474(2):247-251. doi: 10.1007/s00428-018-2463-5. Epub 2018 Oct 4.

11.

Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.

Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.

Clin Cancer Res. 2018 Dec 15;24(24):6277-6287. doi: 10.1158/1078-0432.CCR-18-0063. Epub 2018 Aug 23. Erratum in: Clin Cancer Res. 2019 May 1;25(9):2935.

PMID:
30139880
12.

Three-dimensional ultrasonography of the breast; An adequate replacement for MRI in neoadjuvant chemotherapy tumour response evaluation? - RESPONDER trial.

van Egdom LSE, Lagendijk M, Heijkoop EHM, Koning AHJ, van Deurzen CHM, Jager A, van Lankeren W, Koppert LB.

Eur J Radiol. 2018 Jul;104:94-100. doi: 10.1016/j.ejrad.2018.05.005. Epub 2018 May 5.

PMID:
29857873
13.

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S.

Cancers (Basel). 2018 May 5;10(5). pii: E134. doi: 10.3390/cancers10050134.

14.

Gamma probe and ultrasound-guided fine needle aspiration cytology of the sentinel node (GULF) trial.

Verver D, Oude Ophuis CMC, Koppert LB, de Monyé C, van Deurzen CHM, Koljenović S, Bruining A, van der Hiel B, Ter Meulen S, van Akkooi ACJ, Verhoef C, Grünhagen DJ.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1926-1933. doi: 10.1007/s00259-018-4014-3. Epub 2018 Apr 26.

15.

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL, Hardisson D, Benitez J, Blomqvist C, Bolla MK, Brenner H, Chang-Claude J, Cora R, Couch FJ, Cuk K, Devilee P, Easton DF, Eccles DM, Eilber U, Hartikainen JM, Heikkilä P, Holleczek B, Hooning MJ, Jones M, Keeman R, Mannermaa A, Martens JWM, Muranen TA, Nevanlinna H, Olson JE, Orr N, Perez JIA, Pharoah PDP, Ruddy KJ, Saum KU, Schoemaker MJ, Seynaeve C, Sironen R, Smit VTHBM, Swerdlow AJ, Tengström M, Thomas AS, Timmermans AM, Tollenaar RAEM, Troester MA, van Asperen CJ, van Deurzen CHM, Van Leeuwen FF, Van't Veer LJ, García-Closas M, Figueroa JD.

Sci Rep. 2018 Apr 26;8(1):6574. doi: 10.1038/s41598-018-23733-4.

16.

Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJT, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Pilar Zamora M, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM.

Nat Commun. 2018 Apr 10;9:16193. doi: 10.1038/ncomms16193.

17.

Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

Agahozo MC, Hammerl D, Debets R, Kok M, van Deurzen CHM.

Mod Pathol. 2018 Jul;31(7):1012-1025. doi: 10.1038/s41379-018-0030-x. Epub 2018 Feb 20. Review.

18.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

Severson TM, Kim Y, Joosten SEP, Schuurman K, van der Groep P, Moelans CB, Ter Hoeve ND, Manson QF, Martens JW, van Deurzen CHM, Barbe E, Hedenfalk I, Bult P, Smit VTHBM, Linn SC, van Diest PJ, Wessels L, Zwart W.

Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2.

19.

IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.

Zhang Y, Wester L, He J, Geiger T, Moerkens M, Siddappa R, Helmijr JA, Timmermans MM, Look MP, van Deurzen CHM, Martens JWM, Pont C, de Graauw M, Danen EHJ, Berns EMJJ, Meerman JHN, Jansen MPHM, van de Water B.

Oncogene. 2018 Apr;37(14):1869-1884. doi: 10.1038/s41388-017-0027-9. Epub 2018 Jan 22.

PMID:
29353882
20.

A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer.

Groenendijk FH, Jager A, Cardoso F, van Deurzen CHM.

Breast. 2018 Apr;38:125-131. doi: 10.1016/j.breast.2017.12.015. Epub 2018 Jan 6.

PMID:
29310037
21.

Copy number profiling of oncogenes in ductal carcinoma in situ of the male breast.

Vermeulen MA, Doebar SC, van Deurzen CHM, Martens JWM, van Diest PJ, Moelans CB.

Endocr Relat Cancer. 2018 Mar;25(3):173-184. doi: 10.1530/ERC-17-0338. Epub 2017 Dec 4.

PMID:
29203614
22.

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

Dackus GM, Ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop E, Willems SM, Van Deurzen CH, Groen EJ, Cordoba A, Bart J, Mooyaart AL, van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, Voogd A, Jozwiak K, Hauptmann M, Hoogstraat M, Schmidt MK, Sonke G, van der Wall E, Siesling S, van Diest PJ, Linn SC.

BMJ Open. 2017 Nov 14;7(11):e017842. doi: 10.1136/bmjopen-2017-017842.

23.

Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.

Brouckaert O, Rudolph A, Laenen A, Keeman R, Bolla MK, Wang Q, Soubry A, Wildiers H, Andrulis IL, Arndt V, Beckmann MW, Benitez J, Blomqvist C, Bojesen SE, Brauch H, Brennan P, Brenner H, Chenevix-Trench G, Choi JY, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Eriksson M, Fasching PA, Figueroa J, Flyger H, Giles GG, González-Neira A, Guénel P, Hall P, Hollestelle A, Hopper JL, Ito H, Jones M, Kang D; kConFab, Knight JA, Kosma VM, Li J, Lindblom A, Lilyquist J, Lophatananon A, Mannermaa A, Manoukian S, Margolin S, Matsuo K, Muir K, Nevanlinna H, Peterlongo P, Pylkäs K, Saajrang S, Seynaeve C, Shen CY, Shu XO, Southey MC, Swerdlow A, Teo SH, Tollenaar RAEM, Truong T, Tseng CC, van den Broek AJ, van Deurzen CHM, Winqvist R, Wu AH, Yip CH, Yu JC, Zheng W, Milne RL, Pharoah PDP, Easton DF, Schmidt MK, Garcia-Closas M, Chang-Claude J, Lambrechts D, Neven P.

Breast Cancer Res. 2017 Nov 7;19(1):119. doi: 10.1186/s13058-017-0909-3.

24.

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH.

Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651.

25.

Analysis of clonal expansions through the normal and premalignant human breast epithelium reveals the presence of luminal stem cells.

Cereser B, Jansen M, Austin E, Elia G, McFarlane T, van Deurzen CH, Sieuwerts AM, Daidone MG, Tadrous PJ, Wright NA, Jones L, McDonald SA.

J Pathol. 2018 Jan;244(1):61-70. doi: 10.1002/path.4989. Epub 2017 Nov 23.

26.

Raman spectroscopy for cancer detection and cancer surgery guidance: translation to the clinics.

Santos IP, Barroso EM, Bakker Schut TC, Caspers PJ, van Lanschot CGF, Choi DH, van der Kamp MF, Smits RWH, van Doorn R, Verdijk RM, Noordhoek Hegt V, von der Thüsen JH, van Deurzen CHM, Koppert LB, van Leenders GJLH, Ewing-Graham PC, van Doorn HC, Dirven CMF, Busstra MB, Hardillo J, Sewnaik A, Ten Hove I, Mast H, Monserez DA, Meeuwis C, Nijsten T, Wolvius EB, Baatenburg de Jong RJ, Puppels GJ, Koljenović S.

Analyst. 2017 Aug 21;142(17):3025-3047. doi: 10.1039/c7an00957g. Review.

PMID:
28726868
27.

Focally positive margins in breast conserving surgery: Predictors, residual disease, and local recurrence.

Vos EL, Gaal J, Verhoef C, Brouwer K, van Deurzen CHM, Koppert LB.

Eur J Surg Oncol. 2017 Oct;43(10):1846-1854. doi: 10.1016/j.ejso.2017.06.007. Epub 2017 Jun 23.

PMID:
28688723
28.

Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.

Doebar SC, Sieuwerts AM, de Weerd V, Stoop H, Martens JWM, van Deurzen CHM.

Am J Pathol. 2017 Jul;187(7):1648-1655. doi: 10.1016/j.ajpath.2017.03.012.

PMID:
28634007
29.

Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

Moghadasi S, Grundeken V, Janssen LAM, Dijkstra NH, Rodríguez-Girondo M, van Zelst-Stams WAG, Oosterwijk JC, Ausems MGEM, Oldenburg RA, Adank MA, Blom EW, Ruijs MWG, van Os TAM, van Deurzen CHM, Martens JWM, Schroder CP, Wijnen JT, Vreeswijk MPG, van Asperen CJ.

Clin Genet. 2018 Jan;93(1):52-59. doi: 10.1111/cge.13065. Epub 2017 Sep 25.

PMID:
28589637
30.

Erratum to: gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol.

Oude Ophuis CMC, Koppert LB, de Monyé C, van Deurzen CHM, Koljenović S, van Akkooi ACJ, Verhoef C, Grünhagen DJ.

BMC Cancer. 2017 May 30;17(1):387. doi: 10.1186/s12885-017-3363-9. No abstract available.

31.

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer.

De Marchi T, Timmermans MA, Sieuwerts AM, Smid M, Look MP, Grebenchtchikov N, Sweep FCGJ, Smits JG, Magdolen V, van Deurzen CHM, Foekens JA, Umar A, Martens JW.

Sci Rep. 2017 May 18;7(1):2099. doi: 10.1038/s41598-017-02296-w.

32.

TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial.

Lagendijk M, Vos EL, Koning AHJ, Hunink MGM, Pignol JP, Corten EML, de Monye C, van Deurzen CHM, van Dam JH, Vrijland WW, Contant CME, Verhoef C, van Lankeren W, Koppert LB.

BMC Cancer. 2017 May 17;17(1):336. doi: 10.1186/s12885-017-3280-y.

33.

SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?

Dalm SU, Haeck J, Doeswijk GN, de Blois E, de Jong M, van Deurzen CHM.

J Nucl Med. 2017 Oct;58(10):1609-1614. doi: 10.2967/jnumed.116.189035. Epub 2017 Apr 27.

34.

Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol.

Oude Ophuis CMC, Koppert LB, de Monyé C, van Deurzen CHM, Koljenović S, van Akkooi ACJ, Verhoef C, Grünhagen DJ.

BMC Cancer. 2017 Apr 12;17(1):258. doi: 10.1186/s12885-017-3236-2. Erratum in: BMC Cancer. 2017 May 30;17 (1):387.

35.

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHM.

Eur J Cancer. 2017 Sep;82:219-227. doi: 10.1016/j.ejca.2017.01.034. Epub 2017 Mar 11.

PMID:
28292559
36.

Progressive APOBEC3B mRNA expression in distant breast cancer metastases.

Sieuwerts AM, Schrijver WA, Dalm SU, de Weerd V, Moelans CB, Ter Hoeve N, van Diest PJ, Martens JW, van Deurzen CH.

PLoS One. 2017 Jan 31;12(1):e0171343. doi: 10.1371/journal.pone.0171343. eCollection 2017.

37.

Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer.

Dalm SU, Schrijver WA, Sieuwerts AM, Look MP, Ziel-van der Made AC, de Weerd V, Martens JW, van Diest PJ, de Jong M, van Deurzen CH.

PLoS One. 2017 Jan 20;12(1):e0170536. doi: 10.1371/journal.pone.0170536. eCollection 2017.

38.

Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Dinjens WN, van Marion R, van Diest PJ, Martens JW, van Deurzen CH.

Mod Pathol. 2017 Apr;30(4):509-518. doi: 10.1038/modpathol.2016.229. Epub 2017 Jan 13.

39.

Proteomic characterization of microdissected breast tissue environment provides a protein-level overview of malignant transformation.

Braakman RB, Stingl C, Tilanus-Linthorst MM, van Deurzen CH, Timmermans MA, Smid M, Foekens JA, Luider TM, Martens JW, Umar A.

Proteomics. 2017 Mar;17(5). doi: 10.1002/pmic.201600213.

40.

Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Devilee P, Tollenaar RA, Seynaeve C, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, Martens JW, van Deurzen CH; kConFab Investigators, Bolla MK, Wang Q, Jones M, Schoemaker M, Wesseling J, van Leeuwen FE, Van 't Veer L, Easton D, Swerdlow AJ, Dowsett M, Pharoah PD, Schmidt MK, Garcia-Closas M.

Breast Cancer Res. 2016 Oct 18;18(1):104.

41.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

42.

Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.

Geurts-Giele WR, van Verschuer VM, van Deurzen CH, van Diest PJ, Pedrosa RM, Collée JM, Koppert LB, Seynaeve C, Dinjens WN.

Mod Pathol. 2017 Jan;30(1):15-25. doi: 10.1038/modpathol.2016.145. Epub 2016 Sep 9.

43.

Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study.

van Deurzen CH.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):627-633. Epub 2016 Sep 2.

44.

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.

Liu NQ, De Marchi T, Timmermans A, Trapman-Jansen AM, Foekens R, Look MP, Smid M, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Foekens JA, Martens JW, Umar A.

Sci Rep. 2016 Aug 25;6:32027. doi: 10.1038/srep32027.

45.

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.

Doebar SC, van den Broek EC, Koppert LB, Jager A, Baaijens MHA, Obdeijn IAM, van Deurzen CHM.

Breast Cancer Res Treat. 2016 Jul;158(1):179-187. doi: 10.1007/s10549-016-3862-4. Epub 2016 Jun 18.

46.

Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen.

Doebar SC, de Monyé C, Stoop H, Rothbarth J, Willemsen SP, van Deurzen CH.

Breast. 2016 Jun;27:15-21. doi: 10.1016/j.breast.2016.02.014. Epub 2016 Mar 20.

PMID:
27212695
47.

SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.

van der Willik KD, Timmermans MM, van Deurzen CH, Look MP, Reijm EA, van Zundert WJ, Foekens R, Trapman-Jansen AM, den Bakker MA, Westenend PJ, Martens JW, Berns EM, Jansen MP.

Am J Cancer Res. 2016 Jan 15;6(2):270-84. eCollection 2016.

48.

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.

Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, Phelan CM, Pilarski R, Poppe B, Pylkäs K, Radice P, Rahman N, Rantala J, Rappaport C, Rennert G, Richardson A, Robson M, Romieu I, Rudolph A, Rutgers EJ, Sanchez MJ, Santella RM, Sawyer EJ, Schmidt DF, Schmidt MK, Schmutzler RK, Schumacher F, Scott R, Senter L, Sharma P, Simard J, Singer CF, Sinilnikova OM, Soucy P, Southey M, Steinemann D, Stenmark-Askmalm M, Stoppa-Lyonnet D, Swerdlow A, Szabo CI, Tamimi R, Tapper W, Teixeira MR, Teo SH, Terry MB, Thomassen M, Thompson D, Tihomirova L, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tsimiklis H, Teulé A, Tumino R, Tung N, Turnbull C, Ursin G, van Deurzen CH, van Rensburg EJ, Varon-Mateeva R, Wang Z, Wang-Gohrke S, Weiderpass E, Weitzel JN, Whittemore A, Wildiers H, Winqvist R, Yang XR, Yannoukakos D, Yao S, Zamora MP, Zheng W, Hall P, Kraft P, Vachon C, Slager S, Chenevix-Trench G, Pharoah PD, Monteiro AA, García-Closas M, Easton DF, Antoniou AC.

Nat Commun. 2016 Apr 27;7:11375. doi: 10.1038/ncomms11375.

49.

Genetic predisposition to ductal carcinoma in situ of the breast.

Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, Orr N, Cox A, Cross SS, Dos-Santos-Silva I, Peto J, Swerdlow A, Schoemaker MJ, Bolla MK, Wang Q, Dennis J, Michailidou K, Benitez J, González-Neira A, Tessier DC, Vincent D, Li J, Figueroa J, Kristensen V, Borresen-Dale AL, Soucy P, Simard J, Milne RL, Giles GG, Margolin S, Lindblom A, Brüning T, Brauch H, Southey MC, Hopper JL, Dörk T, Bogdanova NV, Kabisch M, Hamann U, Schmutzler RK, Meindl A, Brenner H, Arndt V, Winqvist R, Pylkäs K, Fasching PA, Beckmann MW, Lubinski J, Jakubowska A, Mulligan AM, Andrulis IL, Tollenaar RA, Devilee P, Le Marchand L, Haiman CA, Mannermaa A, Kosma VM, Radice P, Peterlongo P, Marme F, Burwinkel B, van Deurzen CH, Hollestelle A, Miller N, Kerin MJ, Lambrechts D, Floris G, Wesseling J, Flyger H, Bojesen SE, Yao S, Ambrosone CB, Chenevix-Trench G, Truong T, Guénel P, Rudolph A, Chang-Claude J, Nevanlinna H, Blomqvist C, Czene K, Brand JS, Olson JE, Couch FJ, Dunning AM, Hall P, Easton DF, Pharoah PD, Pinder SE, Schmidt MK, Tomlinson I, Roylance R, García-Closas M, Sawyer EJ.

Breast Cancer Res. 2016 Feb 17;18(1):22. doi: 10.1186/s13058-016-0675-7.

50.

Tumor slice culture system to assess drug response of primary breast cancer.

Naipal KA, Verkaik NS, Sánchez H, van Deurzen CH, den Bakker MA, Hoeijmakers JH, Kanaar R, Vreeswijk MP, Jager A, van Gent DC.

BMC Cancer. 2016 Feb 9;16:78. doi: 10.1186/s12885-016-2119-2.

Supplemental Content

Loading ...
Support Center